The main feature of type 1 diabetes is the destruction of pancreatic β cells that produce insulin. Immunotherapy directed at inhibiting immune interactions between cytokines and islet cells and preserving its functioning is key to reverse the progression of the disease.
IBI-3030 from Innovent Biologics Inc. is a novel antibody-peptide conjugate targeting PCSK9 that shows agonism for GLP-1R, GCGR and GIPR, aimed to confer therapeutic benefit against cardiovascular disease.
Despite the approval of numerous antibody-drug conjugates (ADCs), their therapeutic index remains limited by off-target toxicity resulting from linker instability. To address this challenge, the development of novel ADCs with improved plasma stability and reduced systemic toxicity is critically needed.
Hemab ApS recently presented preclinical data on its human monoclonal antibody against von Willebrand factor (vWF), HMB-002, for the treatment of von Willebrand disease.
CDR-Life Inc. has announced CDR-609 as its next clinical candidate. Built on the company’s proprietary M-gager platform, CDR-609 is a novel T-cell engager targeting LGR5, a surface antigen widely expressed on common solid tumors, including colorectal, gastric, liver and pancreatic cancers.
An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR) agonist that mimics the effects of physical exercise by activating skeletal muscle metabolism. Unlike GLP-1-based treatments such as semaglutide and tirzepatide, this new compound, developed by researchers at the Karolinska Institute, Stockholm University, and the biotech company Atrogi AB, does not suppress appetite or cause muscle loss.
In recognition of the fact that diversity, equity and inclusion are necessary prerequisites for precision medicine, the European Academy of Neurology announced the launch of a DEI Hub at its 11th Congress, which is being held in Helsinki through June 24.
Centre Hospitalier Regional Universitaire de Lille, Centre National de la Recherche Scientifique, INSERM, Institut Pasteur de Lille and the University of Lille have prepared and tested new tricyclic spirolactam compounds reported to be useful for the treatment of tuberculosis.
Glucagon-like peptide 1 receptor (GLP-1R) agonists have been detailed in a Fortvita Biologics Inc. patent. They are reported to be useful for the treatment of arthritis, coronary heart diseases, dementia, diabetes, hyperlipidemia, inflammatory bowel diseases, obesity and substance abuse and dependence.
Nanjing Deheng Pharmaceutical Technology Co. Ltd. and Nanjing Delova Biotech Co. Ltd. have discovered new sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, cough and pruritus.
RSS
